{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:05:07Z","timestamp":1780463107120,"version":"3.54.1"},"reference-count":20,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015096","name":"Canadian Dairy Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.vaccine.2021.08.065","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:00:22Z","timestamp":1630533622000},"page":"5814-5821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial"],"prefix":"10.1016","volume":"39","author":[{"given":"Khalequ","family":"Zaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie D.","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Vanderende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0203-5744","authenticated-orcid":false,"given":"Asma","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9878-5920","authenticated-orcid":false,"given":"Mohammed","family":"Yunus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Snider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepcion F.","family":"Estivariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Steven","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4818","authenticated-orcid":false,"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijeet","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.08.065_b0005","unstructured":"Centers for Disease Control and Prevention. Apparent global interruption of wild poliovirus type 2 transmission. MMWR Morb Mortal Wkly Rep. 2001;50(12):222\u20134."},{"issue":"6261","key":"10.1016\/j.vaccine.2021.08.065_b0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1126\/science.aad7294","article-title":"Eradicating polio","volume":"350","author":"Adams","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2021.08.065_b0015","unstructured":"Global Polio Erradication Iniative. Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication; 2019."},{"issue":"35","key":"10.1016\/j.vaccine.2021.08.065_b0020","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine - worldwide, 2016","volume":"65","author":"Hampton","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5566","key":"10.1016\/j.vaccine.2021.08.065_b0025","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1126\/science.1068284","article-title":"Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus","volume":"296","author":"Kew","year":"2002","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.vaccine.2021.08.065_b0030","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1093\/aje\/kwq320","article-title":"From emergence to eradication: the epidemiology of poliomyelitis deconstructed","volume":"172","author":"Nathanson","year":"2010","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2021.08.065_b0035","unstructured":"No authors listed Meeting of the Strategic Advisory Group of Experts on Immunization, November 2013 - Conclusions and Recommendations. Weekly Epidemiologic Record. 2013;89:20."},{"key":"10.1016\/j.vaccine.2021.08.065_b0040","unstructured":"No authors listed. Meeting of the Strategic Advisory Group of Experts Polio Working Group, April 2017 -Conclusions and Recommendations. Weekly Epidemiologic Record. 2017;92:301\u201320."},{"issue":"5","key":"10.1016\/j.vaccine.2021.08.065_b0045","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa1202541","article-title":"Priming after a fractional dose of inactivated poliovirus vaccine","volume":"368","author":"Resik","year":"2013","journal-title":"N Engl J Med"},{"issue":"10040","key":"10.1016\/j.vaccine.2021.08.065_b0050","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","article-title":"Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial","volume":"388","author":"Asturias","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.vaccine.2021.08.065_b0055","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S1473-3099(20)30555-7","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine schedules for the post-eradication era: a randomised open-label, multicentre, phase 3, non-inferiority trial","volume":"21","author":"Bandyopadhyay","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"42","key":"10.1016\/j.vaccine.2021.08.065_b0060","doi-asserted-by":"crossref","first-page":"937","DOI":"10.15585\/mmwr.mm6842a1","article-title":"Global routine vaccination coverage, 2018","volume":"68","author":"Peck","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2021.08.065_b0065","unstructured":"Global Polio Eradication Initiative. Background and Technical Rational for Introduction of One Dose of Inactivated Polio Vaccine (IPV) in Routine Immunization Schedules. 2015 January 2015."},{"issue":"15","key":"10.1016\/j.vaccine.2021.08.065_b0070","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1056\/NEJMoa054960","article-title":"Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba","volume":"356","author":"The Cuba IPVSCG","year":"2007","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.vaccine.2021.08.065_b0075","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1056\/NEJMoa0909383","article-title":"Fractional doses of inactivated poliovirus vaccine in Oman","volume":"362","author":"Mohammed","year":"2010","journal-title":"N Engl J Med"},{"issue":"48","key":"10.1016\/j.vaccine.2021.08.065_b0080","doi-asserted-by":"crossref","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","article-title":"Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial","volume":"33","author":"Anand","year":"2015","journal-title":"Vaccine"},{"issue":"10191","key":"10.1016\/j.vaccine.2021.08.065_b0085","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/S0140-6736(19)30503-3","article-title":"Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial","volume":"393","author":"Snider","year":"2019","journal-title":"Lancet"},{"issue":"1_suppl_1","key":"10.1016\/j.vaccine.2021.08.065_b0090","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1177\/15648265040251S105","article-title":"Measurement and standardization protocols for anthropometry used in the construction of a new international growth reference","volume":"25","author":"de Onis","year":"2004","journal-title":"Food Nutr Bull"},{"key":"10.1016\/j.vaccine.2021.08.065_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2021.08.065_b0100","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1093\/infdis\/jiu343","article-title":"Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys","volume":"210","author":"Anand","year":"2014","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21011130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:04:57Z","timestamp":1759403097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21011130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":20,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0264410X21011130"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.065","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.08.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}